Oncology Central

Could PD-L1 prove to be an effective therapeutic target for bladder cancer?


Highlighting this years’ American Society for Clinical Oncology (ASCO) conference were presentations focusing on T-cell immune checkpoint blockade as a therapeutic target in solid tumors. Promising results in melanoma, lung and renal cancers have led to further disease-specific Phase I and II trials of immune checkpoint blockade in other solid tumors refractory to treatment.

To view restricted content, please:

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.